Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | VCP | P55072 | 1/20 | 0.34 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.32 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13708602 | 1.00 | IRAK4 (0.40) | IRAK4CHRNB2CHRNA4VCPPFKFB3 | |
| SCHEMBL4084081 | 0.90 | IRAK4 (0.41) | IRAK4ATR | |
| SCHEMBL4097183 | 0.90 | IRAK4 (0.41) | IRAK4ATR | |
| SCHEMBL4084319 | 0.89 | IRAK4 (0.42) | IRAK4ROCK2ROCK1CCNT1CDK9 | |
| SCHEMBL4089120 | 0.89 | IRAK4 (0.42) | IRAK4ROCK2ROCK1CCNT1CDK9 | |
| SCHEMBL4084142 | 0.87 | CCNT1 (0.42) | IRAK4CHRNB2CHRNA4VCPCSNK1E | |
| SCHEMBL4096043 | 0.86 | CHRNA7 (0.38) | VCPPFKFB3ATRCCNT1CDK9 | |
| SCHEMBL4095574 | 0.85 | PFKFB3 (0.34) | VCPPFKFB3ATRMAP3K12BRAF | |
| SCHEMBL4094675 | 0.84 | MAPK1 (0.34) | VCPPFKFB3ATRMAP3K12CCNT1 | |
| SCHEMBL13708605 | 0.84 | MAPK1 (0.34) | VCPPFKFB3ATRMAP3K12CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149468-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-06-11 | — | — | US | claimed |
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-08-18 | — | — | US | claimed |
| US-7582631-B2 | Paget's disease; muscular disorders; cardiovascular disorders; antiinflamamtory agents; antidiabetic agents; autoimmune disease; leukemia | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090149468-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149468-A1 | Substituted heterocyclic compounds and methods of use | HLA-DRB1, PRKDC, NFATC1 | IRAK4 250/4885CHRNB2 1720/4885CHRNA4 1639/4885 |
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | HLA-DRB1, PRKDC, NFATC1 | IRAK4 336/4885CHRNB2 1652/4885CHRNA4 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.